for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Lonza Group AG

LONN.S

Latest Trade

337.00CHF

Change

-3.50(-1.03%)

Volume

242,151

Today's Range

336.40

 - 

340.70

52 Week Range

245.10

 - 

364.00

As of on the Virt-X ∙ Minimum 15 minute delay

Pricing

Previous Close
340.50
Open
340.00
Volume
242,151
3M AVG Volume
7.61
Today's High
340.70
Today's Low
336.40
52 Week High
364.00
52 Week Low
245.10
Shares Out (MIL)
74.02
Market Cap (MIL)
25,356.61
Forward P/E
27.00
Dividend (Yield %)
0.81

Next Event

Lonza Group AG at Baader Helvea AG COO LSI Reverse Roadshow - Basel

Latest Developments

More

Lonza Says Ibex Solutions To Support Genmab Clinical Portfolio

Lonza Announces Extension, Increase Of Term And Revolving Bank Facilities

Celltrion and Lonza sign contract to make Remsima drug substance

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Lonza Group AG

Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.

Industry

Biotechnology & Drugs

Contact Info

Muenchensteinerstrasse 38

+41.61.3168111

https://www.lonza.com/

Executive Leadership

Albert M. Baehny

Independent Chairman of the Board

Marc Funk

Chief Executive Officer, Member of the Executive Committee

Rodolfo Savitzky

Chief Financial Officer, Member of the Executive Committee

Sven Abend

Chief Operating Officer - Specialty Ingredients, Member of the Management Board, Chief Strategy Officer

Fridtjof Helemann

Chief Human Resource Officer, Member of the Executive Committee

Key Stats

2.11 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, CHF)

2016

4.1K

2017

5.1K

2018

5.5K

2019(E)

5.9K
EPS (CHF)

2016

9.047

2017

11.740

2018

11.980

2019(E)

12.609
Price To Earnings (TTM)
39.43
Price To Sales (TTM)
4.66
Price To Book (MRQ)
4.08
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
61.29
LT Debt To Equity (MRQ)
50.97
Return on Investment (TTM)
5.76
Return on Equity (TTM)
4.71

Latest News

Latest News

BRIEF-Lonza Says Ibex Solutions To Support Genmab Clinical Portfolio

* SAYS IBEX SOLUTIONS TO SUPPORT GENMAB’S GROWING CLINICAL PORTFOLIO

Lonza first-half profit plunges, says on track to hit full-year goals

Lonza Group's <LONN.S> first-half profit plunged as it took losses linked to the sale of its water business and as difficulties at its specialty ingredients business continued, though the Swiss drug ingredients maker confirmed full-year targets.

BRIEF-Lonza Expands Bioconjugation Facility

* LONZA EXPANDS BIOCONJUGATION FACILITY AND ANNOUNCES APPROVAL OF THIRD COMMERCIAL ADC

Lonza says on track to hit full-year 2019 targets

Swiss drug ingredients maker Lonza Group said on Wednesday it is on pace to hit its 2019 goal of mid-to-high single-digit sales growth as double-digit gains in its drug and biotech unit in the first half offset weaker business elsewhere.

Lonza fills portfolio hole by buying Novartis drug bottling plant

Lonza Group is buying a drug bottling plant from Novartis in northern Switzerland as the Swiss drug ingredients maker fills a gap in its offering for drugmakers seeking to outsource production.

Lonza snaps up Novartis fill-and-finish facility to expand offering

Lonza Group is buying a sterile fill-and-finish facility from Novartis as the Swiss drug ingredients maker boosts its offering for pharmaceuticals companies.

Lonza carves out Specialty Ingredients business, shares rise

Lonza Group will carve out its Specialty Ingredients (LSI) business and cut around 130 jobs there as it reorganizes a division that has struggled, the Swiss group said on Monday.

BRIEF-Carve-out costs for Lonza Specialty Ingredients Won't Affect 2019 Guideline - CEO

* LONZA GROUP CEO SAYS ADDITIONAL COSTS FOR CARVED-OUT SPECIALTY INGREDIENTS BUSINESS WON'T AFFECT 2019 GUIDELINES Source text for Eikon: Further company coverage: (Reporting By Michael Shields)

REFILE-Lonza to carve out Specialty Ingredients business

Lonza Group will carve out its Specialty Ingredients (LSI) business and cut around 130 jobs there, as it reorganises a division that has struggled this year.

BRIEF-Lonza Group Announced Intention To Proceed With A Carve-Out Of Its Specialty Ingredients Segment (LSI)

* LONZA GROUP AG - INTENTION TO PROCEED WITH A CARVE-OUT OF ITS SPECIALTY INGREDIENTS SEGMENT (LSI)

BRIEF-Lonza says newly aligned specialty ingredients segment performed below expectations in Q1

* OUTLOOK 2019 MAINTAINED AND ACCELERATED PORTFOLIO REVIEW ONGOING

BRIEF-Lonza Group And Chr. Hansen To Establish Joint Venture

* LONZA AND CHR. HANSEN IN JOINT VENTURE TO ACCELERATE MOMENTUM IN MICROBIOME

BRIEF-Lonza Completes Divestment Of Water Care Business

* ANNOUNCED TODAY COMPLETION OF DIVESTMENT OF ITS FORMER WATER CARE BUSINESS AND OPERATIONS TO PLATINUM EQUITY FOR USD 630 MILLION Source text for Eikon: Further company coverage: (Reporting by Berlin Speed Desk)

BRIEF-Lonza Aligns Structure, Creates New Executive Committee Position

* LONZA STRENGTHENS PHARMA, BIOTECH AND NUTRITION OFFERINGS WITH ALIGNED STRUCTURE AND NEW EXECUTIVE COMMITTEE APPOINTMENT

BRIEF-Emerald, Lonza To Manufacture Cannabinoid-Derived Drug Candidate

* EMERALD HEALTH PHARMACEUTICALS AND LONZA ANNOUNCE AGREEMENT FOR MANUFACTURING OF NOVEL CANNABINOID-DERIVED DRUG CANDIDATE

BRIEF-Lonza And Allcells Collaborate On Hematopoietic Primary Cells

* LONZA AND ALLCELLS JOIN FORCES FOR GLOBAL COMMERCIALIZATION OF HEMATOPOIETIC PRIMARY CELLS Source text: https://bit.ly/2GbE1ne Further company coverage: (Reporting by Berlin Speed Desk)

BRIEF-Lonza CEO said he requested fast handover to successor

* LONZA CEO RIDINGER SAYS CHANGE TO INTERNAL SUCCESSOR RIGHT MOVE, IMPORTANT TO HAVE FAST HANDOVER

UPDATE 2-Lonza Group CEO to leave in March, shares slump

* Says to accelerate review of business portfolio (Adds market reaction)

Lonza Group says profit rise driven by pharma, biotech

Lonza Group said its 2018 core operating profit rose 14.1 percent as the Swiss drug ingredients maker was buoyed by strong results in its business supplying the drug and biotech industries.

BRIEF-Lonza Group names pharma exec Funk to replace retiring CEO

* SAYS FUNK IS CURRENTLY CHIEF OPERATING OFFICER OF PHARMA AND BIOTECH DIVISION Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up